NCT00577421View on ClinicalTrials.gov

Study to Assess BMD and Bone Turnover Response to 5 mg Daily Risedronate Treatment in Women With PMO

PHASE3CompletedINTERVENTIONAL

Enrollment

32

Participants

Timeline

Start Date

June 30, 2003

Study Completion Date

January 31, 2006

Conditions

Postmenopausal Osteoporosis

Interventions

DRUG

risedronate

5 mg tablet of risedronate once a day for 2 years

Trial Locations (5)

Unknown

Research Site, Concord

Research Facility, Siena

Research Facility, Warsaw

Research Facility, Barcelona

Research Facility, Gothenburg

Sponsors

Lead Sponsor

Warner Chilcott

Collaborators (1)

All Listed Sponsors

collaborator

Sanofi

INDUSTRY

lead

Warner Chilcott

INDUSTRY